ALPMF News and Press, Astellas Pharma Inc From 02/11/20

Seattle Genetics (NASDAQ: SGEN ) and collaboration partner Astellas Pharma ( OTCPK:ALPMF ) announce updated results from an open-label  Phase 1b/2 clinical trial evaluating the combination of antibody-drug conjugate (ADC) PADCEV (enfortumab vedotin-ejfv) and Merck's Keytruda (pembrol...

One of England's top healthcare watchdogs, the National Institute for Health and Care Excellence (NICE), has officially decided to stay the course and reject AstraZeneca 's (NYSE: AZN) lung cancer drug Tagrisso. A few months ago, the pharmaceutical giant argued that the drug should receive...

Quick Take Aditx Therapeutics ( ADTX ) has filed to raise $10.5 million in an IPO of its common stock and warrants, according to an S-1 registration statement . The company is a pre-clinical developer of immune suppression drugs to assist in organ transplantation procedures. ADTX is sti...

Adaptimmune Therapeutics (NASDAQ: ADAP ) inks an agreement with Astellas Pharma ( OTCPK:ALPMF ) aimed at co-developing and co-commercializing up to three T-cell therapies in cancer. More news on: Adaptimmune Therapeutics plc, Astellas Pharma Inc., Astellas Pharma Inc., Healthcare stocks ...

This past year proved profitable for investors in Incyte (NASDAQ: INCY) and Seattle Genetics (NASDAQ: SGEN) . Handily beating broad market and biotech indexes, these two drug manufacturers hit the $20 billion valuation mark and are poised to continue growing in the coming year -- unless, ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). Banks are making the biggest round of job cuts in four years as they slash costs to deal with a slow...

Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ) acquires Xyphos, gaining the proprietary Advanced Cellular Control through Engineered Ligands (ACCEL) platform to develop new ways to direct immune cells to find, modulate, and destroy targeted cells throughout the body. More news on: Astel...

Under accelerated review status, the FDA approves Seattle Genetics (NASDAQ: SGEN ) and collaboration partners Astellas Pharma's ( OTCPK:ALPMF ) antibody-drug conjugate (ADC) Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial ...

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Eli Lilly's (NYSE: LLY ) Cyramza (ramucirumab), combined with Roche ( OTCQX:RHHBY ) and Astellas Pharma's ( OTCPK:ALPMF ) Tarceva (erlotinib), for the first-line treatment of adult p...

Merger activity increased with five new deals announced and five deals closing. Deal Statistics New Deals The acquisition of Audentes Therapeutics (BOLD) by Astellas Pharma (ALPMF) for $2.65 billion or $60.00 per share in cash. The acquisition of AK Steel Holding Corporation...